AD Pipeline Watch: Zai Lab’s IL-13/IL-31R Bispecific Antibody Shows Promise in Preclinical Pilot Study June 13, 2025
Exploring the Use of Lebrikizumab (Ebglyss, Eli Lilly and Company) in AD Patients With Darker Skin Tones Featuring Dr. Andrew Alexis June 13, 2025
